Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.46 |
| ▸ | CA2 | P00918 | 8/20 | 0.46 |
| ▸ | CA9 | Q16790 | 7/20 | 0.46 |
| ▸ | CA4 | P22748 | 6/20 | 0.46 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA6 | P23280 | 5/20 | 0.46 |
| ▸ | CA5A | P35218 | 5/20 | 0.46 |
| ▸ | CA7 | P43166 | 5/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.46 |
| ▸ | CA3 | P07451 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11328574 | 0.78 | GAA (0.52) | CA1CA2CA9CA4CA12 | |
| SCHEMBL22637253 | 0.77 | CA1 (0.39) | CA1CA2CA9CA4CA12 | |
| SCHEMBL3342012 | 0.75 | CA1 (0.56) | CA1CA2CA9CA4CA12 | |
| SCHEMBL8023195 | 0.74 | L3MBTL1 (0.45) | CA1CA2CA9CA4CA12 | |
| SCHEMBL24769393 | 0.74 | TSHR (0.49) | ALDH1A1TSHRPOLB | |
| SCHEMBL31032058 | 0.74 | TSHR (0.49) | ALDH1A1TSHRPOLB | |
| SCHEMBL26514797 | 0.73 | CA1 (0.78) | CA1CA2CA9CA4CA12 | |
| SCHEMBL8434850 | 0.73 | CA1 (0.50) | CA1CA2CA9CA4CA12 | |
| SCHEMBL11689176 | 0.73 | ALDH1A1 (0.72) | CA1CA2CA9CA4CA12 | |
| SCHEMBL282188 | 0.72 | L3MBTL1 (0.62) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377084-B2 | ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2025-08-05 | — | — | US | disclosed |
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| US-20230000851-A1 | ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-11-03 | — | — | US | disclosed |
| EP-4058429-A1 | ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-09-21 | — | — | EP | disclosed |
| EP-3966196-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020225569-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020225569-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2020-11-12 | — | — | WO | disclosed |
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2393781-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | CHP1, ERAP1, QSOX1 | CA1 841/4885CA2 596/4885CA9 261/4885 |
| US-20220347176-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | ERAP1, CHP1, QSOX1 | CA1 861/4885CA2 479/4885CA9 281/4885 |
| US-12377084-B2 | ERAP1 modulators | ERAP1, NR1I3, HRH4 | CA1 322/4885CA2 434/4885CA9 541/4885 |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | CA1 4329/4885CA2 3152/4885CA9 4839/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | CA1 786/4885CA2 453/4885CA9 257/4885 |
| US-20230000851-A1 | ERAP1 MODULATORS | ERAP1, NR1I3, HRH4 | CA1 322/4885CA2 434/4885CA9 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.